We next investigated whether we could exploit the ASL relationship between XPA and MK2 (Fig. 2) for treatment of murine lung adenocarcinomas using our nanoplexes to co-deliver siRNAs against both MK2 and XPA in vivo. Here, MAPKAPK2 is linked to lung adenocarcinoma.